ReviewJournal of thrombosis and haemostasis : JTH2015
Manipulating megakaryocytes to manufacture platelets ex vivo.
Review in Journal of thrombosis and haemostasis : JTH, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Highly efficient generation of mature megakaryocytes and functional platelets from human embryonic stem cells.Stem cell research & therapy · 2024Article
- Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets.International journal of hematology · 2023Review
- A brief molecular insight of COVID-19: epidemiology, clinical manifestation, molecular mechanism, cellular tropism and immuno-pathogenesis.Molecular and cellular biochemistry · 2021Review
- A comprehensive investigation on liver regeneration: a meta-analysis and systems biology approach.Clinical and experimental hepatology · 2021Article
- [Cultured platelets].Bulletin de l'Academie nationale de medecine · 2020Review
- Platelet and liver regeneration after liver surgery.Surgery today · 2020Review
- Mechanisms involved in the development of thrombocytopenia in patients with COVID-19.Thrombosis research · 2020Review
- Functional properties of human platelets derived in vitro from CD34Scientific reports · 2020Article
- A comparison of haematopoietic stem cells from umbilical cord blood and peripheral blood for platelet production in a microfluidic device.Vox sanguinis · 2019Article
- Bringing Induced Pluripotent Stem Cell Technology to the Bedside.JMA journal · 2018Article
- A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production.Blood advances · 2018Article
- In vitro culture of murine megakaryocytes from fetal liver-derived hematopoietic stem cells.Platelets · 2018Article
- On the Way toFrontiers in medicine · 2018Review
- Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017Review
- Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice.Stem cell reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, platelet transfusion has proven a reliable way to treat patients suffering from thrombocytopenia or similar ailments. An undersupply of donors, however, has demanded alternative platelet sources. Scientists have therefore sought to recapitulate the biological events that convert hematopoietic stem cells into platelets in the laboratory. Such platelets have shown good function and potential for treatment. Yet the number manufactured ex vivo falls well short of clinical application. Part of the reason is the remarkable gaps in our understanding of the molecular mechanisms driving platelet formation. Using several stem cell sources, scientists have progressively clarified the chemical signaling and physical microenvironment that optimize ex vivo platelets and reconstituted them in synthetic environments. Key advances in cell reprogramming and the ability to propagate self-renewal have extended the lifetime of megakaryocytes to increase the pool of platelet progenitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.